

Original article

Reaction time and visual memory in connection to alcohol use in schizophrenia and schizoaffective disorder

Atiqul Haq Mazumder^{1*}, Jennifer Barnett², Nina Lindberg³, Minna Holm⁴, Markku Lähteenvuo^{5,6**}, Kaisla Lahdensuo^{6**,7}, Martta Kerkelä¹, Jarmo Hietala^{8,9}, Erkki Isometsä³, Olli Kampman^{10,11}, Tuula Kiesepä^{3,6**,7}, Tuomas Jukuri^{1,6**}, Katja Häkkinen^{5,6**}, Erik Cederlöf⁴, Willehard Haaki^{6**,8}, Risto Kajanne⁶, Asko Wegelius^{3,4,6**}, Teemu Männynsalo^{6**,12}, Jussi Niemi-Pynttari^{6**,12}, Kimmo Suokas^{6**,10}, Jouko Lönnqvist^{4,13}, Solja Niemelä^{8,9}, Jari Tiihonen^{5,14,15}, Tiina Paunio^{3,4,13}, Annamari Tuulio-Henriksson¹⁶, Aarno Palotie^{6**,7,17,18}, Jaana Suvisaari⁴, Juha Veijola^{1,19}

¹ Department of Psychiatry, University of Oulu, FI-90014 Oulu, Finland.

² University of Cambridge, Cambridge CB25 9TU, UK.

³ University of Helsinki, Helsinki University Hospital, Psychiatry, FI-00029 Helsinki, Finland.

⁴ Mental Health Unit, Finnish Institute for Health and Welfare (THL), FI-00271 Helsinki, Finland.

⁵ Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, FI-70240 Kuopio, Finland.

⁶ Institute for Molecular Medicine Finland (FIMM), University of Helsinki, FI-00014 Helsinki, Finland, *years 2016–2018

⁷ Mehiläinen, FI-00260 Helsinki, Finland.

⁸ Department of Psychiatry, University of Turku, FI-20014 Turku, Finland.

⁹ Department of Psychiatry, Turku University Hospital, FI-20521 Turku, Finland.

¹⁰ Faculty of Medicine and Health Technology, Tampere University, FI-33014 Tampere, Finland.

¹¹ Department of Psychiatry, Pirkanmaa Hospital District, FI-33521 Tampere, Finland.

¹² Social Services and Health Care Sector, City of Helsinki, FI-00099 Helsinki, Finland.

¹³ Department of Psychiatry, University of Helsinki, FI-00014 Helsinki, Finland.

¹⁴ Department of Clinical Neuroscience, Karolinska Institutet, SE-17177 Stockholm, Sweden.

¹⁵ Center for Psychiatry Research, Stockholm City Council, SE-11364 Stockholm, Sweden.

¹⁶ Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, FI-00014 Helsinki, Finland.

¹⁷ Stanley Center for Psychiatric Research, The Broad Institute of MIT (Massachusetts Institute of Technology) and Harvard, MA-02142 Cambridge, Massachusetts, USA.

¹⁸ Analytical and Translational Genetics Unit, Massachusetts General Hospital, MA-02114 Boston, Massachusetts, USA.

¹⁹ Department of Psychiatry, Oulu University Hospital, FI-90220 Oulu, Finland.

*Corresponding author. Email: atiqul.mazumder@oulu.fi atiq10@gmail.com ORCID ID: <https://orcid.org/0000-0002-2148-4070>

**Years 2016-2018.

Abstract: Purpose of the study was to explore the association of cognition with hazardous drinking, binge drinking and alcohol use disorder in schizophrenia and schizoaffective disorder. Cognitive deficits are common in schizophrenia. Alcohol might be associated with additional cognitive impairment in schizophrenia patients. The study population included 3362 schizophrenia and schizoaffective disorder patients in Finland. Hazardous drinking was screened with the AUDIT-C (Alcohol Use Disorders Identification Test for Consumption) screening tool. Binge drinking was obtained from the AUDIT-C. Alcohol use disorder (AUD) diagnoses were obtained from the national registrar data. Participants performed two computerized tasks from the Cambridge automated neuropsychological test battery (CANTAB) on tablet computer: the 5-choice serial reaction time task (5-CSRTT), or, reaction time (RT) test and the Paired Associative Learning (PAL) test. Association of alcohol use with RT test and PAL test was analyzed with log-linear regression and logistic regression, respectively. After adjustment for age, education and age at first psychotic episode, hazardous drinking in females was associated with lower median RT. Compared to never binge drinkers, male and female participants drinking 6 or more doses of alcohol monthly or less had lower

median RT. In the PAL test both first trial memory score (FTMS) and total errors adjusted score (TEAS) were associated with better performance in males drinking 6 or more doses of alcohol weekly or more and in females drinking 6 or more doses monthly or less. Higher PAL TEAS was associated with AUD in females. Some positive associations between alcohol and cognition were found in male and female schizophrenia and schizoaffective disorder patients with hazardous drinking and binge drinking.

Keywords: Cognition; Visual memory; Reaction time; Alcohol; schizophrenia and schizoaffective disorder.

1. Introduction

Cognitive dysfunction is a persistent, disabling hallmark of schizophrenia found to be present in about 75% of schizophrenia patients [1]. It is associated with the severity of illness in schizophrenia [2]. Schizophrenia patients with comorbid AUD demonstrate marked impairment in multiple cognitive domains [3,4,5,6,7]. Most affected cognitive domains are sustained attention, concept formation and non-verbal cognitive flexibility [8].

Individuals with schizophrenia have three times more risk of heavy alcohol use than general population [10]. AUD is the second most common comorbidity in patients with schizophrenia, after nicotine dependence [11]. Systematic review and meta-analysis of 123 research papers published during 1990-2017 revealed 24.3% lifetime prevalence of AUD among subjects with schizophrenia [12].

About 90% of people who drink excessively would not be expected to meet the clinical diagnostic criteria for having AUD [13], rather could be screening-positive for hazardous drinking or binge (heavy episodic) drinking.

Hazardous drinking is a pattern of alcohol consumption that increases the risk of harmful consequences for the user or others. Hazardous drinking patterns are of public health significance despite the absence of any current disorder in the individual alcohol user [14,15,16,17].

Binge drinking, or, heavy episodic drinking (HED) is the most common pattern of excessive alcohol use [13,18,19,20].

In general population males drink more alcohol than females [21]. However, in recent years male to female ratios for alcohol use, problematic alcohol use and alcohol-related harm have declined considerably [22,23].

Studies in general populations suggest that mild to moderate alcohol drinking might not decline cognition [24,25,26,27]. In schizophrenia patients, association of cognition with different drinking patterns has not been fully studied yet.

The main aim of the present study was to explore the association of reaction time and visual memory with different drinking patterns in persons with schizophrenia and schizoaffective disorder diagnoses.

The specific research aims are to study:

1. The association of hazardous drinking with reaction time and visual memory in persons with schizophrenia and schizoaffective disorder.
2. The association of binge drinking with reaction time and visual memory in persons with schizophrenia and schizoaffective disorder.

3. The association of alcohol use disorder with reaction time and visual memory in persons with schizophrenia and schizoaffective disorder.

2. Materials and Methods

2.1. Approval of the full study

The Finnish Super study approval number from the Finnish Institute for Health and Welfare (THL) was THL/1007/5.05.00/2017.

2.2. Participants

The participants of this study were part of the study population of the SUPER (Suomalainen psykoosisairauksien perinnöllisyysmekanismien tutkimus/ Finnish study for the hereditary mechanisms behind psychotic illnesses)- study, which is part of the international Stanley Global Neuropsychiatric Genomics Initiative, USA. The SUPER-study collected data during the period 2016-2019 from people with a lifetime diagnosis of psychosis in Finland to identify gene loci and gene variations predisposing to psychotic illnesses and comorbid diseases. Voluntary subjects with a diagnosis of schizophrenia spectrum psychotic disorder, bipolar I disorder or major depressive disorder with psychotic features were recruited from psychiatric inpatient and outpatient departments, general health care centers and supported housings. Participants were identified through local healthcare centers throughout the country from all levels of healthcare to ensure inclusive sampling. Subjects had also been recruited via advertisements on local newspapers.

Out of the original sample of 10555 participants, 6769 had clinical diagnosis of schizophrenia and schizoaffective disorder. Among those, 228 had missing information on alcohol use or education. Of the remaining 6541 participants, 1435 did not complete the cognitive tests or had duplicate test results. Finally, we had 3362 participants after excluding 1744 who did not live independently (living in supported housing, hospital or unknown residence) as alcohol use is restricted in those places. (Figure 1).

Research manuscripts reporting large datasets that are deposited in a publicly available database should specify where the data have been deposited and provide the relevant accession numbers. If the accession numbers have not yet been obtained at the time of submission, please state that they will be provided during review. They must be provided prior to publication.

2.3. Schizophrenia and schizoaffective disorder diagnoses

The diagnoses of schizophrenia and schizoaffective disorder were obtained from the Care Register for Health Care (CRHC) of the Finnish Institute for Health and Welfare. In Finland the International Classification of Disease (ICD) system has been used in psychiatric diagnoses. In this study schizophrenia diagnoses included the code 295 according to ICD-8; and ICD-9 and F20 according to ICD-10 and schizoaffective disorder diagnoses included the code 295.7 according to ICD-8; and ICD-9 and F25 according to ICD-10. ICD-8 was used during 1968-1986, ICD-9 during 1987-1995 and ICD-10 since 1996 in Finland.

2.4. Hazardous drinking screening

Hazardous drinking was screened using the AUDIT-C questionnaire to assess an individual's alcohol consumption frequency ('how often do you have a drink containing alcohol?'), quantity ('how many drinks containing alcohol do you have on a typical day when you are drinking?'), and bingeing ('how often do you have six or more drinks on

one occasion?'). AUDIT-C is derived from the hazardous alcohol use domain of the Alcohol Use Disorders Identification Test (AUDIT) questionnaire [28]. It has three questions and is scored on a scale of 0-12. Each AUDIT-C question has 5 answer choices valued from 0 points to 4 points.

Cutoff scores for hazardous drinking vary considerably [19,29]. In the present study we used cutoff scores recommended by Finnish National Guidelines; a score of 6 or more in males, and 5 or more in females [30].

2.5. Binge drinking screening

There exist several definitions of binge drinking [31,32]. In the present study binge drinking was screened using the bingeing question ('how often do you have six or more drinks on one occasion?') of the AUDIT C screening questionnaire.

2.6. Alcohol use disorder diagnoses

The diagnoses of alcohol use disorder were obtained from the CRHC data following ICD-8 291, 303, ICD-9 291, 3030, 3050A, ICD-10 F10 during 1969-2018.

2.7. Cognitive measures

Participants performed two computerized tasks from The Cambridge neuropsychological test automated battery (CANTAB) on tablet computer; the 5-choice serial reaction time task (5-CRTT) and the paired associative learning (PAL) task for the assessment of reaction time (RT) and visual memory respectively.

The PAL test is sensitive to the integrity of the frontal and medial temporal lobes, in particular the hippocampal and para-hippocampal regions, which corresponds to the changes seen in Alzheimer's Disease (AD). The PAL test provides markers for impaired visual memory in first-episode psychosis [33], normal variation in midlife cognitive function as well as earliest signs of Alzheimer's related decline [34,35].

These tasks were chosen to produce relevant information of cognition in psychotic disorders in the very restricted assessment schedule. The instructions to both tests were translated into Finnish. The CANTAB tests were performed before venipuncture in order to avoid malfunction of the arm due to pain or bandaging. The study nurses were given standardized instructions on how to guide the study subjects in performing the CANTAB test beforehand.

In the RT-test, the participant must select and hold a button at the bottom of the screen. Circles are presented above; five for the five-choice mode. A yellow dot will appear in one of the circles, and the participant must react as soon as possible, releasing the button at the bottom of the screen, and selecting the circle in which the dot appeared (Cambridge Cognition, Reaction time). In the RT-test we used two continuous measurements: median of the five-choice reaction time and standard deviation (SD) of the five-choice reaction time. Median of the five-choice reaction time is the median duration between the onset of the stimulus and the release of the button. Standard deviation of the five-choice reaction time is the standard deviation of the time taken to touch the stimulus after the button has been released. Both variables were calculated for correct, assessed trials where the stimulus could appear in any of five locations.

In the PAL-test we assessed visual memory using the primary outcome variable of 'total errors adjusted'. Here we assessed two different dichotomized variables, using data from Northern Finland Birth Cohort 1966 (NFBC 1966) as a reference data [36]. The NFBC 1966 consists of all born with expected date in the year 1966. The data used in this study consist of a 46-year follow-up when cohort members took the PAL-test during clinical examination (N=5,608). For the first trial memory score, the 15th percentile (score of 17

or more) was used as a cut-off for good performance in PAL test in the recent study, meaning the SUPER study population did better performance than 15% of NFBC 1966 study population. Scores for total errors adjusted of NFBC66, the 50th percentile (10 error score or less) was used as a cut-off for good performance in PAL test in the recent study, meaning the SUPER study population made better error score than a 50% of NFBC 1966 study population. First Trial Memory Score is how many patterns the participant correctly places on the first attempt at each problem, while Total Errors Adjusted Score reflects how quickly the participant learns when the participant has multiple attempts at each problem.

2.8. Confounding factors

Age, education [37] and age of first psychotic episode [4] have effects on cognitive functioning, hence we considered them be the confounding variables in this study.

2.7.1. Age

Cognition is negatively associated with increased age in healthy populations [38] and debatably in alcohol users [39]. Age of the participants was calculated using participation date and year of birth of the participant. Age was used as continues variable.

2.8.2. Education

Education is strongly associated with cognitive performance [40]. The questions and possible answers addressing education of the participants were: 'What is your basic education?' (1= less than the primary school, 2= matriculation examination, 3= middle school, 4= part of general upper secondary school or general upper secondary education certificate, 5= part of a middle school or primary school less than 9 years, 6= primary school, 7= Four year elementary school). During the analysis we combined classes 1, 3, 4, 5, 6 and 7 as 'No matriculation examination' versus class 2 ('Matriculation examination').

2.8.3. Age of first psychotic episode

We used age at first psychotic episode as a marker of severity of the illness. Research shows that the earlier is the schizophrenia and schizoaffective disorder development, the mores severe is the illness in terms of the disease pattern and cognitive decline [41,42]. The data of age at first psychotic episode were obtained form the CRHC and were used in this research as continuous variable.

2.9. Statistical methods

We evaluated the association between cognition and alcohol use by using four different cognition variables; median and standard deviation of RT, PAL FTMS and PAL total errors adjusted. Alcohol use was measured by different variables; dichotomous hazard drinking variable derived from AUDIT score; classified variable of binge drinking obtained from AUDIT questionnaire; and dichotomous variable indicating, if the study subject had had alcohol disorder diagnosis. We assessed crude models and also adjusted models with age, age of first psychosis episode and education. Association between RT-test and alcohol use was analyzed with log-linear regression, and $e\beta$ with 95% confidence intervals (CI) are reported. Association between PAL-test and alcohol use was analyzed with logistic regression and odds ratios (OR) with 95% CI are reported.

All analyses were conducted separately in males and females. Males and females have differences in performing selected cognitive tests [43,44,45]. Also, males and females have differences in alcohol use patterns [18,46,47,48].

3. Results

This section may be divided by subheadings. It should provide a concise and precise description of the experimental results, their interpretation, as well as the experimental conclusions that can be drawn.

3.1. Background factors and alcohol use patterns

Of the participants 51% were males and 49 % were females. Mean age was 45 years for males and 46 years for females. One third of the males and two fifth of the females had highest basic educational of 12 years (matriculation). Mean age at first psychotic episode was 27 years for male and 28 for female. Four fifth of the males and three fifth of the females were living alone. Most of the participants were on psychotropic medication (Table 1).

All types of alcohol use patterns were more common in males than in females. Every fifth male and every tenth female schizophrenia and schizoaffective disorder patients had positive screening for hazardous drinking. About half of the male and one third of the female were screened as binge drinkers, mostly binge drinking monthly or less frequently. About one third of male and one sixth of female schizophrenia and schizoaffective disorder patients had a lifetime diagnosis of AUD (Table 1).

Lower age associated with hazardous drinking both in males and females. In females lower age of onset and types of household associated with hazardous drinking (Supplementary table 1).

Median RT was 435 milliseconds (SD 50 milliseconds), PAL median FTMS was 8 and median total errors adjusted was 33 (Supplementary table 2).

Association between background factors and AUD with RT P-values are reported in supplementary table 3. Association between background factors and alcohol use patterns with PAL scores are reported in supplementary table 4 and supplementary table 5.

3.2. Association of reaction time and visual memory with hazardous drinking in schizophrenia and schizoaffective disorder patients

Crude median reaction time was shorter and less divers in male and female schizophrenia and schizoaffective disorder patients with hazardous drinking compared to those without hazardous drinking. After adjustment for age, education and age at first psychotic episode hazardous drinking in females associated with lower median RT (OR 0.97, 95% CI 0.95-0.99). After adjustment, reaction time was less diverse in male schizophrenia and schizoaffective disorder patients with hazardous drinking compared to male schizophrenia patients without hazardous drinking (Table 2). Association between hazardous drinking and RT scores are reported in supplementary table 6.

Crude PAL first trial memory score was higher in male and crude PAL total errors adjusted score were higher in both female schizophrenia and schizoaffective disorder patients with hazardous drinking compared to those without hazardous drinking (Table 2).

3.3. Association of reaction time and visual memory with binge drinking in schizophrenia and schizoaffective disorder patients

Crude median reaction time was shorter and less diverse in male schizophrenia and schizoaffective disorder patients binge drinking weekly compared to those binge-drinking monthly or less and in male schizophrenia and schizoaffective disorder patients binge drinking monthly or less compared to those never binge drinking. Adjusted median reaction time was shorter in male schizophrenia patients binge drinking monthly or less compared to those binge-drinking never (OR 0.98, CI 0.96-0.99). After adjustment, reaction time was less diverse in male schizophrenia and schizoaffective disorder patients binge drinking weekly compared to those binge-drinking monthly or less. Crude median reaction time was shorter in female schizophrenia and schizoaffective disorder patients binge

drinking weekly compared to those binge-drinking monthly or less and in female schizophrenia and schizoaffective disorder patients binge drinking monthly or less compared to those never binge drinking (OR 0.98, CI 0.96-1.00). Both crude and adjusted median reaction time were less diverse in female schizophrenia and schizoaffective disorder patients binge drinking monthly or less compared to those binge-drinking drinking never (Table 3).

Crude PAL FTMS and crude PAL total errors adjusted score were higher in male schizophrenia and schizoaffective disorder patients binge drinking weekly (for FTMS OR 2.09, CI 1.17-3.62; for total errors adjusted OR 0.63, CI 0.43-0.95) compared to those binge drinking monthly or less and in male schizophrenia and schizoaffective disorder patients binge drinking monthly or less compared to those never binge drinking. Crude PAL first trial memory score and crude PAL total errors adjusted score were higher in female schizophrenia and schizoaffective disorder patients binge drinking monthly or less compared to those never binge drinking (for FTMS OR 1.64, CI 1.08-2.49; for total errors adjusted OR 0.74, CI 0.56-0.97) and crude PAL total errors adjusted score was higher in female schizophrenia and schizoaffective disorder patients binge drinking weekly compared to those binge drinking monthly or less (Table 3).

3.4. Association of reaction time and visual memory with alcohol use disorder in schizophrenia and schizoaffective disorder patients

There was no significant difference in crude or adjusted reaction time in male and female schizophrenia and schizoaffective disorder patients with or without a lifetime history of alcohol use disorder (Table 4).

Crude PAL total errors adjusted score was higher in female schizophrenia and schizoaffective disorder patients with a lifetime history of alcohol use disorder compared to those without alcohol use disorder (OR 1.51, CI 1.06-2.17) (Table 4).

3.5. Figures, Tables and Schemes

Figure 1. flowchart showing selection of study population




Table 1. Background factors and alcohol use patterns in schizophrenia and schizoaffective disorder.

	Male	Female
	N = 1711	N = 1651
Age (mean (SD))	44.5 (12.8)	46.3 (13.2)
<i>Education</i>		
No matriculation examination (%)	1191 (69.6)	981 (59.4)
Matriculation examination (%)	520 (30.4)	670 (40.6)
Age at first psychotic episode (Mean (SD))	26.84 (8.25)	28.01 (9.51)
<i>Household pattern</i>		
Alone (%)	1338 (78.2)	1065 (64.5)
With children without spouse (%)	7 (0.4)	63 (3.8)
With parents or siblings (%)	166 (9.7)	82 (5.0)
With spouse (%)	140 (8.2)	339 (20.5)
With spouse and children (%)	60 (3.5)	102 (6.2)
<i>Current Psychotropic medications</i>		
No (%)	42 (2.45)	33 (2.00)
Yes (%)	1668 (97.49)	1614 (97.76)
Missing (%)	1 (0.06)	4 (0.24)
<i>Hazardous drinking*</i>		
No (%)	1276 (74.6)	1390 (84.2)
Yes (%)	435 (25.4)	261 (15.8)
<i>Binge drinking**</i>		
Never (%)	903 (52.8)	1134 (68.7)
Monthly or less frequently (%)	596 (34.8)	434 (26.3)
Weekly or more frequently (%)	212 (12.4)	83 (5.0)
<i>Alcohol use disorder</i>		
No (%)	1212 (70.8)	1395 (84.5)
Yes (%)	499 (29.2)	256 (15.5)

*AUDIT-C cutoff scores for hazardous drinking were ≥ 6 for males and ≥ 5 for females

** ≥ 6 doses in single occasion

Table 2. Association of RT test and PAL test with hazardous drinking in schizophrenia and schizoaffective disorder.

	<i>Five choice reaction time*</i>				<i>Five choice reaction time*</i>			
	Median				SD			
	Crude		Adjusted ^a		Crude		Adjusted ^a	
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
<i>Male</i>								
<i>Hazardous drinking</i>	0.97 (0.95-0.99)	0.002	0.99 (0.97-1.01)	0.323	0.86 (0.81-0.91)	<.001	0.92 (0.87-0.98)	0.005
<i>Female</i>								
<i>Hazardous drinking</i>	0.94 (0.92-0.97)	<.001	0.97 (0.95-0.99)	0.010	0.89 (0.83-0.96)	0.002	0.98 (0.92-1.05)	0.606
	<i>PAL first trial memory score**</i>				<i>PAL total errors adjusted score**</i>			
	Better performance than 15% of NFBC 1966 members				Higher error scores than 50% of NFBC 1966 members			
	Crude		Adjusted ^a		Crude		Adjusted ^a	
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
<i>Male</i>								
<i>Hazardous drinking</i>	1.76 (1.13-2.66)	0.001	1.21 (0.77-1.86)	0.397	0.56 (0.43-0.73)	<.001	0.79 (0.60-1.05)	0.106
<i>Female</i>								
<i>Hazardous drinking</i>	1.58 (0.95-2.52)	0.064	1.07 (0.63-1.74)	0.798	0.58 (0.43-0.80)	<.001	0.88 (0.64-1.22)	0.440

^a Adjusted with age, education and age at first psychotic episode

* Analyzed with log-linear regression

** Analyzed with logistic regression

Table 3. Association of RT test and PAL test with binge drinking in schizophrenia and schizoaffective disorder.

	<i>Five choice reaction time*</i>		<i>Five choice reaction time*</i>	
	Median		SD	
	Crude	Adjusted ^a	Crude	Adjusted ^a

	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
<i>Binge drinking</i>								
<i>Male</i>								
<i>Monthly or less frequently</i>	0.95 (0.93-0.96)	<.001	0.98 (0.96-0.99)	0.009	0.85 (0.81-0.90)	<.001	0.94 (0.89-1.00)	0.040
<i>Weekly or more frequently</i>	0.96 (0.94-0.99)	0.002	0.98 (0.96-1.00)	0.102	0.83 (0.77-0.90)	<.001	0.89 (0.83-0.96)	0.003
<i>Female</i>								
<i>Monthly or less frequently</i>	0.94 (0.93-0.96)	<.001	0.98 (0.96-1.00)	0.015	0.81 (0.76-0.86)	<.001	0.91 (0.86-0.96)	0.001
<i>Weekly or more frequently</i>	0.95 (0.91-0.99)	0.007	0.97 (0.93-1.01)	0.114	0.87 (0.77-0.98)	0.027	0.94 (0.84-1.06)	0.307
<i>PAL first trial memory score**</i>				<i>PAL total errors adjusted score**</i>				
Better performance than 15% of NFBC 1966 members				Higher error scores than 50% of NFBC 1966 members				
Crude		Adjusted ^a		Crude		Adjusted ^a		
OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	
<i>Binge drinking</i>								
<i>Male</i>								
<i>Monthly or less frequently</i>	1.80 (1.17-2.77)	0.008	0.99 (0.63-1.55)	0.876	0.48 (0.37-0.62)	<.001	0.82 (0.63-1.09)	0.170
<i>Weekly or more frequently</i>	2.99 (1.70-5.07)	<.001	2.09 (1.17-3.62)	0.010	0.45 (0.31-0.65)	<.001	0.63 (0.43-0.95)	0.023
<i>Female</i>								
<i>Monthly or less frequently</i>	2.56 (1.71-3.81)	<.001	1.64 (1.08-2.49)	0.019	0.46 (0.35-0.59)	<.001	0.74 (0.56-0.97)	0.029
<i>Weekly or more frequently</i>	1.43 (0.49-3.33)	0.456	1.01 (0.34-2.41)	0.983	0.44 (0.27-0.74)	0.001	0.61 (0.36-1.06)	0.071

^a Adjusted with age, education and age at first psychotic episode

* Analyzed with log-linear regression

** Analyzed with logistic regression

Table 4. Association of RT test and PAL test with alcohol use disorder in schizophrenia and schizoaffective disorder.

<i>Five choice reaction time*</i>				<i>Five choice reaction time*</i>			
Median				SD			
Crude		Adjusted ^a		Crude		Adjusted ^a	
OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value

<i>Male</i>									
<i>Alcohol use disorder</i>	1.01 (0.99-1.02)	0.545	1.00 (0.99-1.02)	0.785	1.02 (0.96-1.08)	0.482	1.00 (0.95-1.06)	0.833	
<i>Female</i>									
<i>Alcohol use disorder</i>	0.99 (0.96-1.01)	0.246	0.99 (0.96-1.00)	0.228	1.03 (0.96-1.11)	0.413	1.03 (0.96-1.11)	0.371	
<i>PAL first trial memory score**</i>					<i>PAL total errors adjusted**</i>				
Better performance than 15% of NFBC 1966 members					Higher error scores than 50% of NFBC 1966 members				
Crude		Adjusted			Crude		Adjusted		
OR (95% CI)	p-value	OR (95% CI)	p-value		OR (95% CI)	p-value	OR (95% CI)	p-value	
<i>Male</i>									
<i>Alcohol use disorder</i>	0.71 (0.45-1.09)	0.131	0.88 (0.55-1.36)	0.567	1.36 (1.05-1.77)	0.021	1.14 (0.86-1.51)	0.364	
<i>Female</i>									
<i>Alcohol use disorder</i>	0.53 (0.28-0.94)	0.043	0.57 (0.29-1.02)	0.076	1.57 (1.13-2.22)	0.009	1.51 (1.06-2.17)	0.024	

^a Adjusted with age, education and age at first psychotic episode

* Analyzed with log-linear regression

** Analyzed with logistic regression

Supplementary table 1 Association between background factors and hazardous drinking in schizophrenia and schizoaffective disorder.

	<i>Male</i>			<i>Female</i>		
	Hazardous drinking			Hazardous drinking		
	No	Yes	p	No	Yes	p
<i>n</i>	1276	435		1390	261	
<i>Age</i>	45.79 (13.03)	40.84 (11.54)	<0.001	47.45 (13.11)	40.19 (11.97)	<0.001

<i>Education</i>	No matriculation examination	889 (69.7)	302 (69.4)		818 (58.8)	163 (62.5)	
	Matriculation examination	387 (30.3)	133 (30.6)	0.971	572 (41.2)	98 (37.5)	0.308
<i>Age at first psychotic episode</i>		26.77 (8.48)	27.04 (7.57)	0.561	28.36 (9.71)	26.14 (8.13)	0.001
<i>Household pattern</i>	Alone	986 (77.3)	352 (80.9)	0.307	895 (64.4)	170 (65.1)	0.045
	With children without spouse	6 (0.5)	1 (0.2)		60 (4.3)	3 (1.1)	
	With parents or siblings	132 (10.3)	34 (7.8)		73 (5.3)	9 (3.4)	
	With spouse	103 (8.1)	37 (8.5)		275 (19.8)	64 (24.5)	
	With spouse and children	49 (3.8)	11 (2.5)		87 (6.3)	15 (5.7)	
	<i>Psychotropic medication</i>	No	35 (2.7)	7 (1.6)		30 (2.2)	3 (1.1)
	Yes	1240 (97.2)	428 (98.4)		1356 (97.6)	258 (98.9)	
	Missing	1 (0.1)	0 (0.0)	0.352	4 (0.3)	0 (0.0)	0.385

Supplementary table 2 Distribution of RT median, RT SD, PAL first trial memory scores (FTMS) and PAL total errors adjusted in study population.

	<i>Min</i>	<i>1st Qu.</i>	<i>Median</i>	<i>Mean</i>	<i>3rd Qu.</i>	<i>Max</i>
<i>RT Median</i>	288	298	434.5	450.2	482	1610
<i>RT SD</i>	14.78	37.98	49.95	66.50	69.87	922.02
<i>PAL FTMS</i>	0.0	4.0	8.0	8.3	12	20
<i>PAL Total errors adjusted</i>	0.0	14	35	33.16	50	70

Supplementary table 3. RT median and RT SD P-values for background factors and alcohol use disorder in schizophrenia and schizoaffective disorder.

P-values

	Male		Female		Test
	RT		RT		
	median	SD	median	SD	
<i>Age</i>	<.001	<.001	<.001	<.001	Spearman
<i>Education</i>	0.563	0.104	<.001	<.001	Spearman
<i>Age at first psychotic episode</i>	<.001	<.001	<.001	<.001	Spearman
<i>Alcohol use disorder</i>	0.445	0.245	0.178	0.211	Point biserial

Supplementary table 4. PAL first trial memory scores (FTMS) for background factors and alcohol use patterns in schizophrenia and schizoaffective disorder.

	<i>Male</i>			<i>Female</i>		
	PAL FTMS			PAL FTMS		
	0	1	p	0	1	p
<i>n</i>	1462	79		1361	100	
<i>Age</i>	44.86 (12.58)	33.77 (9.41)	<0.001	46.28 (12.97)	37.44 (10.87)	<0.001
<i>Education</i>	Matriculation examination	35 (44.3)	0.018	564 (41.4)	58 (58.0)	0.002
	No matriculation examination	44 (55.7)		797 (58.6)	42 (42.0)	
<i>Age at first psychotic episode</i>		24.38 (5.93)	0.008	28.11 (9.69)	25.93 (7.69)	0.028
<i>Household pattern</i>	Alone	50 (63.3)	0.002	888 (65.2)	49 (49.0)	<0.001

<i>Psychotropic medication</i>	With children without spouse	5 (0.3)	1 (1.3)		45 (3.3)	10 (10.0)	
	With parents or siblings	137 (9.4)	12 (15.2)		66 (4.8)	7 (7.0)	
	With spouse	109 (7.5)	8 (10.1)		277 (20.4)	20 (20.0)	
	With spouse and children	49 (3.4)	8 (10.1)		85 (6.2)	14 (14.0)	
	No	34 (2.3)	7 (8.9)		26 (1.9)	5 (5.0)	
	Yes	1427 (97.6)	72 (91.1)		1334 (98.0)	94 (94.0)	
<i>Hazardous drinking</i>	Missing	1 (0.1)	0 (0.0)	0.002	1 (0.1)	1 (1.0)	0.006
	No	1101 (75.3)	51 (64.6)	0.044	1146 (84.2)	80 (80.0)	0.335
	Yes	361 (24.7)	28 (35.4)		215 (15.8)	20 (20.0)	
<i>Binge drinking</i>	Never	784 (53.6)	30 (38.0)		937 (68.8)	53 (53.0)	
	Monthly or less frequently	505 (34.5)	31 (39.2)	0.004	352 (25.9)	44 (44.0)	<0.001
	Weekly or more frequently	173 (11.8)	18 (22.8)		72 (5.3)	3 (3.0)	
<i>Alcohol use disorder</i>	No	1037 (70.9)	62 (78.5)	0.188	1143 (84.0)	90 (90.0)	0.145
	Yes	425 (29.1)	17 (21.5)		218 (16.0)	10 (10.0)	

Supplementary table 5. PAL total errors adjusted scores for background factors and alcohol use patterns in schizophrenia and schizoaffective disorder.

	<i>Male</i>			<i>Female</i>			
	PAL total errors adjusted			PAL total errors adjusted			
	0	1		0	1		
<i>n</i>	241	1300		297	1164		
<i>Age</i>	35.46 (10.11)	45.93 (12.43)	<0.001	37.82 (10.90)	47.68 (12.76)	<0.001	
<i>Education</i>	No matriculation examination	129 (53.5)	925 (71.2)	129 (43.4)	710 (61.0)		
	Matriculation examination	112 (46.5)	375 (28.8)	<0.001	168 (56.6)	454 (39.0)	<0.001
<i>Age at first psychotic episode</i>	24.34 (5.99)	27.23 (8.45)	<0.001	25.94 (7.70)	28.47 (9.94)	<0.001	
<i>Household pattern</i>	Alone	174 (72.2)	1038 (79.8)	0.031	167 (56.2)	770 (66.2)	<0.001
	With children without spouse	1 (0.4)	5 (0.4)		23 (7.7)	32 (2.7)	

	With parents or siblings	30 (12.4)	119 (9.2)		19 (6.4)	54 (4.6)	
	With spouse	20 (8.3)	97 (7.5)		56 (18.9)	241 (20.7)	
	With spouse and children	16 (6.6)	41 (3.2)		32 (10.8)	67 (5.8)	
<i>Psychotropic medication</i>	No	11 (4.6)	30 (2.3)		10 (3.4)	21 (1.8)	
	Yes	230 (95.4)	1269 (97.6)		286 (96.3)	1142 (98.1)	
	Missing	0 (0.0)	1 (0.1)	0.124	1 (0.3)	1 (0.1)	0.143
<i>Hazardous drinking</i>	No	166 (68.9)	986 (75.8)	0.027	239 (80.5)	987 (84.8)	0.085
	Yes	75 (31.1)	314 (24.2)		58 (19.5)	177 (15.2)	
<i>Binge drinking</i>	Never	100 (41.5)	714 (54.9)		170 (57.2)	820 (70.4)	
	Monthly or less frequently	106 (44.0)	430 (33.1)	0.001	111 (37.4)	285 (24.5)	<0.001
	Weekly or more frequently	35 (14.5)	156 (12.0)		16 (5.4)	59 (5.1)	
<i>Alcohol use disorder</i>	No	186 (77.2)	913 (70.2)	0.035	259 (87.2)	974 (83.7)	0.160
	Yes	55 (22.8)	387 (29.8)		38 (12.8)	190 (16.3)	

Supplementary table 6. RT median and RT SD for hazardous drinking in schizophrenia and schizoaffective disorder.

		<i>Male</i>			<i>Female</i>		
		Hazardous drinking			Hazardous drinking		
		0	1	p	0	1	p
<i>n</i>		1276	435		1390	261	
<i>RT</i>	Median	453 (96.06)	438.30 (79.04)	0.004	455.75 (98.50)	426.66 (64.39)	<.001
	SD	67.93 (71.75)	53.65 (32.57)	<.001	70.60 (75.62)	59.26 (54.18)	0.021

4. Discussion

4.1. Main findings

Our findings did not support our hypothesis that alcohol use is associated with additional cognitive impairment in schizophrenia and schizoaffective disorder patients. In contrast, crude median reaction time was significantly shorter in female schizophrenia and schizoaffective disorder patients with hazardous drinking. Crude PAL total errors adjusted score were significantly higher in male and female schizophrenia and

schizoaffective disorder patients with hazardous drinking. Crude PAL first trial memory score and crude PAL total errors adjusted score were significantly higher in male and female schizophrenia and schizoaffective disorder patients binge drinking monthly or less compared to those never binge drinking.

4.2. Comparison with other studies

There hardly exist any studies investigating association of different alcohol use patterns in schizophrenia and schizoaffective disorder patients hence it is difficult to compare our findings with other studies.

Most studies investigating cognitive impact of alcohol in schizophrenia patients with comorbid AUD revealed negative association between alcohol use and cognitive function [6,7,49,50,51,52]. On the other hand, some studies suggested that AUD had no additive effects on cognitive impairment in schizophrenia patients [53,54,55], or had positive associations with social cognition [56,57,58,59], task making and the speed processing domains [60].

Meta-analysis of 6 research findings published during 1996-2009 revealed that younger (<30 years) schizophrenia patients with comorbid alcohol use disorders had better cognition than schizophrenia patients without AUD. In contrast, older (> 40 years) schizophrenia patients with comorbid alcohol use disorders had worse cognition than their non-comorbid counterparts [5]. A systematic review of research papers published during 1990-2012 revealed that cognition was more preserved in schizophrenia patients with comorbid substance/ alcohol use disorders compared schizophrenia patients without comorbidity [61]. It is likely that unmeasured confounding contributes to the discrepant findings in previous studies.

General population cross-sectional studies investigating effects of alcohol on cognitive function revealed that moderate to heavy drinking was associated with cognitive decline [62,63,64,65] and mild to moderate drinking was associated with either no effects on cognition [66,67] or cognitive enhancement [65,68,69,70,71].

Most cohort studies in the general population addressing the same issue revealed a positive correlation between light / light to moderate alcohol use and cognitive function [26,27,72,73,74] whereas other cohort study found no association between light to moderate alcohol consumption and better or worse cognitive functions [75,76,77]. One study reported a positive association between moderate to heavy drinking and cognitive function [78]. In contrast, another cohort study revealed negative association between heavy alcohol use and cognitive function in normal population [79]. One cohort study found dose-response positive association of alcohol use and cognitive function compared to abstainers and former drinkers [80]. Another cohort study revealed significant cognitive impairment in low functioning non-drinkers and light to moderate drinkers and high functioning non-drinkers [81].

A brief review of 29 studies (2003-2013) revealed that acute alcohol mostly impaired executive function in normal population [82]. In contrast, A systematic review of 143 studies (1977-2011) revealed that light to moderate alcohol use did not impair cognition in young male and female individuals and reduced the risk of all forms of dementia and cognitive decline in older individuals [83]. Another systematic review of 28 reviews (2000-2017) revealed that light to moderate alcohol use in middle to late adulthood was associated with a decreased risk of cognitive impairment and dementia [25]. Meta-analysis of 27 cohort studies (2007-2018) revealed that moderate alcohol use improved cognition insignificantly among male and slightly among female compared to current non-drinkers [24]. Moderate alcohol has been found to be associated with reduced amyloid-beta deposition in human brain [84].

Study findings suggesting positive association between alcohol and cognition could be attributed by unmeasured or residual confounding factors [85,86] like: smoking [87], drink type [88], drink pattern [89], personality [87,90], intelligence [76,91,92], educational attainment [93,94], potential abstainer errors [95,96,97,98], reverse causality bias [99], recall error [100] within person temporal variation [101,102], ascertainment of diseases [103]

and sociability effect of alcohol [104]. Study findings suggesting positive association between alcohol and cognition could be attributed by poor motivation [105,106,107].

Animal-model studies suggested alcohol to be associated with cognition negatively through decreasing cell density in the cerebral cortex [108], altering accumbal cholinergic interneurons [109] and positively through enhancing brain metabolite clearance [110], activating vagus nerve [111], anti-oxidant system [112,113,114,115] and other biological processes [116,117,118]. However, none of these findings have so far been confirmed to be causally important.

Epidemiological studies suggested that apparent befitting effects of alcohol might largely be non-causal [27,119,120,121,122]. More research is needed for further clarification [123].

4.3. Strength

We were able to use a very large sample of schizophrenia and schizoaffective disorder patients to investigate cognitive impact of different alcohol use patterns. We studied multiple alcohol use patterns in the same study population, and used age, education and age of onset of schizophrenia and schizoaffective disorder as potential confounding variables.

Although long-term antipsychotic medication might be associated with additional loss of both gray and white matters in schizophrenia [124], in our study we did not confound antipsychotic medication because 98% of the study population was on antipsychotic medication hence it would not make any statistically significant differences.

We have included all schizophrenia and schizoaffective disorder patients living independently and excluded those whose living circumstances might affect their alcohol use.

4.4. Limitations

We used only two tests from CANTAB. Our study was cross-sectional, not longitudinal. Our study was cross-sectional, not longitudinal. We did not use information about the onset of alcohol use, any recent changes in drinking habits or any previous history of abstinence. We also did not differentiate previous alcohol users from never-alcohol users.

We did not use information about poly-substance use and smoking. We did specify psychotropic medications. First generation antipsychotics have been found to be associated with increased volume of basal ganglia, namely globes pallidus, which might be reversed on switching into second-generation antipsychotics and clozapine [125,126]. However, antipsychotic induced brain volume loss has never been established to be associated with additional cognitive decline [12].

4.5. What is already known on this subject?

- Alcohol use disorder decline cognition in schizophrenia and schizoaffective disorder patients
- Mild alcohol use is not associated with impaired cognition in normal population.

4.6. What this study adds?

- Mild alcohol use is not associated with additional cognitive impairment in schizophrenia and schizoaffective disorder patients.

5. Conclusions

No additional cognitive impairment was associated with both male and female schizophrenia and schizoaffective disorder patients with hazardous drinking, binge drinking and alcohol use disorder. Some positive association between alcohol and cognition were found in terms of shorter crude median reaction time in female and higher crude PAL total errors adjusted score in male and female schizophrenia and schizoaffective disorder patients with hazardous drinking, higher crude PAL first trial memory score and crude PAL total errors adjusted score in male and female schizophrenia and schizoaffective disorder patients binge drinking monthly or less compared to those never binge drinking. Further genetic epidemiological studies could help resolving alcohol and cognition correlation-causality-reverse causality debate.

6. Patents

This section is not mandatory but may be added if there are patents resulting from the work reported in this manuscript.

Supplementary Materials: The following are available online at https://drive.google.com/drive/folders/1-9PUv7ZxZ9cSTE8RD_0sAPgV7NZfTsVq , Supplementary tables 1-6.

Author Contributions: All authors have contributed to the conception and design of the study as well as collection of data from various sources. SS performed the analyses. All authors were involved in text editing and discussion of findings. All authors have approved of the final version of the manuscript.

Funding: The work was supported by a grant from the Stanley Center for Psychiatric Research, Broad institute, 75 Ames Street, Cambridge, MA 02142, USA. (Grant no. IORG0000717, IRB00003181, FWA00004167).

The Principal author was supported by the Marie Skłodowska-Curie Action co-funding of regional, national, and international programmes (COFUND) (Grant Agreement no. 713606) for his doctoral programme (MSC-COFUND, I4FUTURE). The Principal author was also supported by the Iso-Mällisen Foundation (Iso-Mällisen Säätiö) through a medical grant of EUR 4,000 for the year 2019 (Grant no. 0400 584622).

Institutional Review Board Statement: Prior to seeking study permissions, a statement (202/13/03/00/2015) pertaining to the ethical considerations of the study was requested from the Coordinating Ethics Committee of the The Hospital District of Helsinki and Uusimaa, which is responsible for nationwide ethical statements. After receiving a favorable statement (HUS/1842/2016) the permissions to conduct the study was sought and obtained from all participating healthcare organizations individually. Permissions for use of national registries were obtained from relevant authorities.

The research was conducted also according to the guidelines of the following research ethics documents: the Responsible conduct of research and procedures for handling allegations of misconduct in Finland (http://www.tenk.fi/sites/tenk.fi/files/HTK_ohje_2012.pdf) and,

The European Code of Conduct for Research Integrity, revised edition 2017 (<http://www.tenk.fi/sites/tenk.fi/files/ALLEA-European-Code-of-Conduct-for-Research-Integrity-2017.pdf>)

Informed Consent Statement: Written informed consent was obtained from all participants. They were informed that participating in or abstaining from the study would not affect the treatment of the study patients.

Study subjects were also informed that they could withdraw their consent at any time, at which point any samples or data stored from them would be destroyed. Data already used in analysis, if not possible to remove from the completed analyses, would never be used in the future, unless a part of a large summary dataset. If the subject was in involuntary psychiatric care or the study nurse had any doubts on the subject's ability to give informed consent, permission would be asked to contact the attending physician of the subject to obtain a statement whether the subject was able to give informed consent to participate in the study. Patients under guardianship were excluded from the study as well as all minors.

From all study participants written informed consent for publication of the study results without disclosing their identities have been taken.

Data Availability Statement: Raw data and materials used for this study are available on request.

Acknowledgments: The authors are grateful to the participants and SUPER-Study staffs.

Conflicts of Interest: None of the authors has any conflicts of interest associated with this study. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: grant support for the submitted work is detailed above; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. However, Jennifer Barnett has been working in Cambridge Cognition since 2016.

References

1. Bosia M, Buonocore M, Bechi M, et al (2018) Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of Metabolic Syndrome on Cognitive Remediation's Outcome. *Front Psychiatry*. 9:647. doi:10.3389/fpsyt.2018.00647
2. Vacca A, Longo R, Mencar C (2019) Identification and evaluation of cognitive deficits in schizophrenia using "Machine learning". *Psychiatr Danub*. 31(Suppl 3):261-264.
3. Anda L, Brønnick KK, Johannessen JO, et al (2019) Cognitive Profile in Ultra High Risk for Psychosis and Schizophrenia: A Comparison Using Coordinated Norms. *Front Psychiatry* 10:695. doi:10.3389/fpsyt.2019.00695
4. Sheffield JM, Karcher NR, Barch DM (2018) Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective. *Neuropsychol Rev* 28(4):509-533. doi:10.1007/s11065-018-9388-2
5. Potvin S, Stavro K, Pelletier J (2012) Paradoxical cognitive capacities in dual diagnosis schizophrenia: the quest for explanatory factors. *J. Dual. Diagn* 8 (1):35–47.
6. Manning V, Betteridge S, Wanigaratne S, Best D, Strang J, Gossop M (2009) Cognitive impairment in dual diagnosis inpatients with schizophrenia and alcohol use disorder. *Schizophr Res*; 114(1-3):98-104.
7. Mohamed S, Bondi MW, Kasckow JW (2006) Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia. *Int J Geriatr Psychiatry* 21(8):711–718.
8. Tyburski, E., Pełka-Wysiecka, J., Mak, M., Samochowiec, A., Bieńkowski, P., & Samochowiec, J. (2017). Neuropsychological Profile of Specific Executive Dysfunctions in Patients with Deficit and Non-deficit Schizophrenia. *Frontiers in psychology*, 8, 1459. <https://doi.org/10.3389/fpsyg.2017.01459>

9. Yu M, Tang X, Wang X, et al (2015) Neurocognitive Impairments in Deficit and Non-Deficit Schizophrenia and Their Relationships with Symptom Dimensions and Other Clinical Variables. *PLoS One*. 10(9):e0138357. Published 2015 Sep 18. doi:10.1371/journal.pone.0138357
10. Hartz SM, Pato CN, Medeiros H, et al (2014) Comorbidity of Severe Psychotic Disorders with Measures of Substance Use. *JAMA Psychiatry* 71(3):248–254. doi:10.1001/jamapsychiatry.2013.3726
11. Leposavić L, Dimitrijević D, Đorđević S, Leposavić I, Balkoski GN (2015) Comorbidity of harmful use of alcohol in population of schizophrenic patients. *Psychiatr Danub* 27(1):84-9.
12. Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB (2018) Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. *Drug Alcohol Depend* 191:234–258. doi:10.1016/j.drugalcdep.2018.07.011
13. Esser MB, Hedden SL, Kanny D, Brewer RD, Gfroerer JC, Naimi TS (2014) Prevalence of alcohol dependence among US adult drinkers, 2009–2011. *Prev Chronic Dis*. 11:140329. doi: <http://dx.doi.org/10.5888/pcd11.140329>.
14. Ng Fat L, Bell S, Britton A (2020) A life-time of hazardous drinking and harm to health among older adults: findings from the Whitehall II prospective cohort study. *Addiction* 10.1111/add.15013. doi:10.1111/add.15013
15. Fujii H, Nishimoto N, Yamaguchi S, et al (2016) The Alcohol Use Disorders Identification Test for Consumption (AUDIT-C) is more useful than pre-existing laboratory tests for predicting hazardous drinking: a cross-sectional study. *BMC Public Health* 16:379. Published 2016 May 10. doi:10.1186/s12889-016-3053-6
16. Rehm J, Anderson P, Manthey J, Shield KD, Struzzo P, Wojnar M, Gual A (2003) Alcohol Use Disorders in Primary Health Care: What Do We Know and Where Do We Go? *Alcohol Alcohol*. 2015 Nov 15. pii: abv127. [Equip ahead of print]. 7. Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. *Cost Eff Resour Alloc* 1(1):8.
17. Babor TF, Longabaugh R, Zweben A, Fuller R K, Stout R L, Anton R F, Randall C L (1994) Issues in the definition and measurement of drinking outcomes in alcoholism treatment research. *Journal of Studies on Alcohol* s12, 101-111
18. Berg NJ, Kiviruusu OH, Lintonen TP, Huurre TM (2019) Longitudinal prospective associations between psychological symptoms and heavy episodic drinking from adolescence to midlife. *Scand J Public Health* 47(4):420–427. doi:10.1177/1403494818769174

19. Sacks JJ, Gonzales KR, Bouchery EE, Tomedi LE, Brewer RD (2010) National and State Costs of Excessive Alcohol Consumption. *Am J Prev Med*. 2015;49(5):e73-e79. doi:10.1016/j.amepre.2015.05.031
20. Stahre M, Roeber J, Kanny D, Brewer RD, Zhang X (2014) Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States. *Prev Chronic Dis* 11:130293. doi: <http://dx.doi.org/10.5888/pcd11.130293>.
21. Wilsnack RW, Wilsnack SC, Kristjanson AF, Vogeltanz-Holm ND, Gmel G (2009) Gender and alcohol consumption: patterns from the multinational GENACIS project. *Addiction* 104(9):1487-1500. doi:10.1111/j.1360-0443.2009.02696.x
22. Slade T, Chapman C, Swift W, et al (2016) Birth cohort trends in the global epidemiology of alcohol use and alcohol-related harms in men and women: systematic review and meta-regression *BMJ Open* 6: e011827. doi: 10.1136/bmjopen-2016-011827
23. Mäkelä P, Tigerstedt C, Mustonen H (2012) The Finnish drinking culture: change and continuity in the past 40 years. *Drug Alcohol Rev* 31(7):831-840. doi:10.1111/j.1465-3362.2012.00479.x
24. Brennan SE, McDonald S, Page MJ, et al (2020) Long-term effects of alcohol consumption on cognitive function: a systematic review and dose-response analysis of evidence published between 2007 and 2018. *Syst Rev* 9(1):33. doi:10.1186/s13643-019-1220-4
25. Rehm J, Hasan OSM, Black SE, Shield KD, Schwarzingler M (2019) Alcohol use and dementia: a systematic scoping review. *Alzheimers Res Ther* 11:1. [PMC free article] [PubMed] [Google Scholar]
26. Koch M, Fitzpatrick AL, Rapp SR, et al (2019) Alcohol Consumption and Risk of Dementia and Cognitive Decline Among Older Adults With or Without Mild Cognitive Impairment. *JAMA Netw Open* 2(9):e1910319. doi:10.1001/jamanetworkopen.2019.10319
27. Piumatti G, Moore SC, Berridge DM, Sarkar C, Gallacher J (2018) The relationship between alcohol use and long-term cognitive decline in middle and late life: a longitudinal analysis using UK Biobank. *J Public Health (Oxf)* 40(2):304-311. doi:10.1093/pubmed/idx186
28. Frank D, DeBenedetti AF, Volk RJ, Williams EC, Kivlahan DR, Bradley KA (2008) Effectiveness of the AUDIT-C as a screening test for alcohol misuse in three race/ethnic groups. *J Gen Intern Med* 23(6):781-787. doi:10.1007/s11606-008-0594-0
29. Public Health England. Alcohol use screening tests (2017) Available at: <https://www.gov.uk/government/publications/alcohol-use-screening-tests>.

30. Lintonen T, Niemelä S, Mäkelä P (2019) Alkoholinkäytön hälytysrajan ylittäviä käyttäjiä on Suomessa vähintään viisi prosenttia väestöstä. *LÄÄKETIETEELLINEN AIKAKAUSKIRJA DUODECIM*. 135(16):1459-66. <https://www.duodecimlehti.fi/lehti/2019/16/duo15071>
31. National Institute of Alcohol Abuse and Alcoholism (2004) NIAAA council approves definition of binge drinking. *NIAAA Newsletter*. 3:3.
32. UK CMOs Report (2016) https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/545937/UK_CMOs__report.pdf
33. Barnett JH, Sahakian BJ, Werners U et al (2005) Visuospatial learning and executive function are independently impaired in first-episode psychosis. *Psychol Med* 35:1031–1041.
34. Bekrater-Bodmann R, Löffler A, Silvoni S, et al (2019) Tablet-based sensorimotor home-training system for amnesic mild cognitive impairments in the elderly: design of a randomised clinical trial. *BMJ Open*. 9(8):e028632. Published 2019 Aug 2. doi:10.1136/bmjopen-2018-028632
35. Juncos-Rabadán O, Pereiro AX, Facal D, Lojo C, Caamaño JA, Sueiro J, et al. Prevalence and correlates of mild cognitive impairment in adults aged over 50 years with subjective cognitive complaints in primary care centers. *Geriatr Gerontol Int*. 2014;14(3):667–73.
36. Taivalantti M, Barnett JH, Halt AH, Koskela J, Auvinen J, Timonen M, Järvelin MR, Veijola J (2020) Depressive symptoms as predictors of visual memory deficits in middle-age. *J Affect Disord*. 1; 264:29-34. doi: 10.1016/j.jad.2019.11.125. Epub 2019 Nov 30.
37. van Hooren SA, Valentijn AM, Bosma H, Ponds RW, van Boxtel MP, Jolles J (2007) Cognitive functioning in healthy older adults aged 64-81: a cohort study into the effects of age, sex, and education. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn* 14(1):40-54. doi:10.1080/138255890969483
38. Andersson C, Marklund K, Walles H, Hagman G, Miley-Akerstedt A (2020) Lifestyle Factors and Subjective Cognitive Impairment in Patients Seeking Help at a Memory Disorder Clinic: The Role of Negative Life Events. *Dement Geriatr Cogn Disord*. 24:1-11. doi: 10.1159/000505573.
39. Strandberg AY, Trygg T, Pitkälä KH, Strandberg TE (2018) Alcohol consumption in midlife and old age and risk of frailty: Alcohol paradox in a 30-year follow-up study. *Age Ageing*. 47(2):248–254. doi:10.1093/ageing/afx165
40. Krahn D, Freese J, Hauser R et al (2003) Alcohol use and cognition at mid-life: the importance of adjusting for baseline cognitive ability and educational attainment. *Alcohol Clin Exp Res* 27(7): 1162–6.

41. Bora, E (2015). Neurodevelopmental origin of cognitive impairment in schizophrenia. *Psychological Medicine*, 45(1), 1-9. doi:10.1017/S0033291714001263
42. Frangou S (2010). Cognitive function in early onset schizophrenia: a selective review. *Frontiers in human neuroscience*, 3, 79. <https://doi.org/10.3389/neuro.09.079.2009>.
43. Lee JK, Son YJ (2018) Gender Differences in the Impact of Cognitive Function on Health Literacy among Older Adults with Heart Failure. *Int J Environ Res Public Health*. 15(12):2711. Published 2018 Dec 1. doi:10.3390/ijerph15122711
44. Voyer D, Voyer SD, Saint-Aubin J (2017) Sex differences in visual-spatial working memory: A meta-analysis. *Psychon Bull Rev* 24, 307–334. <https://doi.org/10.3758/s13423-016-1085-7>
45. Herlitz A, Dekhtyar S, Asperholm M, & Weber D (2016). Gender differences in memory and cognition. In: *Encyclopedia of Geropsychology*. pp. 1-7 Singapore: Springer. ISBN 978-981-287-080-3 DOI:10.1007/978-981-287-080-3_225-1.
46. Dir AL, Bell RL, Adams ZW, Hulvershorn LA (2017). Gender Differences in Risk Factors for Adolescent Binge Drinking and Implications for Intervention and Prevention. *Frontiers in Psychiatry* volume 8; 22 . <https://doi.org/10.3389/fpsy.2017.00289>
47. Hughes TL, Wilsnack SC, Kantor LW (2016) The Influence of Gender and Sexual Orientation on Alcohol Use and Alcohol-Related Problems: Toward a Global Perspective. *Alcohol Research: Current Reviews*. 38(1):121-132.
48. Kanny D, Naimi TS, Liu Y, Lu H, Brewer RD (2018) Annual Total Binge Drinks Consumed by U.S. Adults, 2015 external icon. *Am J Prev Med* 54:486–496.
49. Manning V, Wanigaratne S, Best D, Strathdee G, Schrover I, Gossop M (2007) Screening for cognitive functioning in psychiatric outpatients with schizophrenia, alcohol dependence, and dual diagnosis. *Schizophr Res*. 91(1-3):151-158. doi:10.1016/j.schres.2006.11.019
50. Thoma RJ, Hanoln FM, Miller GA et al (2006) Neuropsychological and sensory gating deficits related to remote alcohol abuse history in schizophrenia. *J Int Neuropsychol Soc*. 12(1): 34–44.
51. Bowie CR, Serper MR, Riggio S, Harvey PD (2005) Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients. *Schizophr Bull*. 31(1):175–182.
52. Allen DN, Goldstein G, Forman SD et al (2000) Neurologic examination abnormalities in schizophrenia with and without a history of alcoholism. *Neuropsychiatry. Neuropsychiatry Neuropsychol Behav Neurol*. 13(3):184–187.

53. Buleyko AA, Soldatkin VA, Murina IV, et al (2019) [Does alcohol influence the cognitive functions of schizophrenic patients?] *Zhurnal Nevrologii i Psikhiiatrii Imeni S.S. Korsakova*. 119(7):14-19. DOI: 10.17116/jnevro201911907114.
54. Allen, D. N., Goldstein, G., & Aldarondo, F. (1999). Neurocognitive dysfunction in patients diagnosed with schizophrenia and alcoholism. *Neuropsychology*, 13, 62–68. doi:10.1037/0894-4105.13.1.62
55. Nixon SJ, Hallford HG, Tivis RD (1996) Neurocognitive function in alcoholic, schizophrenic, and dually diagnosed patients. *Psychiatry Res*. 64:35–45.
56. Gizewski ER, Müller BW, Scherbaum N, Lieb B, Forsting M, Wiltfang J, Leygraf N, Schiffer B (2013) The impact of alcohol dependence on social brain function. *Addict. Biol* 18, 109–120. [PubMed] [Google Scholar]
57. Potvin S, Mancini-Marie A, Fahim C, Mensour B, Stip E (2007) Processing of social emotion in patients with schizophrenia and substance use disorder: an fMRI study. *Soc Neurosci* 2(2):1060116. 10.1080/17470910701376787 [PubMed] [CrossRef] [Google Scholar]
58. Mancini-Marie A, Potvin S, Fahim C, Beauguard M, Mensour B, Stip E (2006) Neural correlates of the affect regulation model in schizophrenia patients with substance use history: a functional magnetic resonance imaging study. *J Clin Psychiatry* 67:342–350.
59. Carey KB, Carey MP, Simons JS (2003) Correlates of substance use disorder among psychiatric outpatients: Focus on cognition, social role functioning, and psychiatric status. *J Nerv Ment Dis*. 191: 300–308.
60. Potvin S, Joyal CC, Pelletier J, Stip E (2008) Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. *Schizophr Res* 100(1-3):242-51.
61. Thoma P, Daum I ((2013) Comorbid substance use in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. *Psychiatry Clin Neurosci*. 67:367–83. doi: 10.1111/pcn.12072.
62. Bartholow BD, Fleming KA, Wood PK, et al (2018) Alcohol effects on response inhibition: Variability across tasks and individuals. *Exp Clin Psychopharmacol*. 2018;26(3):251-267. doi:10.1037/pha0000190
63. Mayhugh RE, Moussa MN, Simpson SL, et al (2016) Moderate-Heavy Alcohol Consumption Lifestyle in Older Adults Is Associated with Altered Central Executive Network Community Structure during Cognitive Task. *PLoS One*. 11(8):e0160214. Published 2016 Aug 5. doi:10.1371/journal.pone.0160214

64. Carrilho PE, Santos MB, Piasecki L, Jorge AC (2013) Marchiafava-Bignami disease: a rare entity with a poor outcome. *Rev Bras Ter Intensiva*. 25(1):68-72. doi:10.1590/s0103-507x2013000100013
65. Kim JW, Lee DY, Lee BC, et al (2012) Alcohol and cognition in the elderly: a review. *Psychiatry Investig*. 9(1):8-16. doi:10.4306/pi.2012.9.1.8
66. Moussa MN, Simpson SL, Mayhugh RE, et al (2015) Long-term moderate alcohol consumption does not exacerbate age-related cognitive decline in healthy, community-dwelling older adults. *Front Aging Neurosci*. 6:341. Published 2015 Jan 5. doi:10.3389/fnagi.2014.00341
67. Sabia S, Elbaz A, Britton A, et al (2014) Alcohol consumption and cognitive decline in early old age. *Neurology*. 82(4):332-339. doi:10.1212/WNL.000000000000063
68. Reas ET, Laughlin GA, Kritz-Silverstein D, Berrett-Connor E, McEvoy LK (2016) Moderate, regular alcohol consumption is associated with higher cognitive function in older, community-dwelling adults. *J. Prev. Alzheimer's Dis*. 3 105–113. [PMC free article] [PubMed] [Google Scholar]
69. Panza F, Frisardi V, Seripa D, et al (2012) Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective?. *Int J Geriatr Psychiatry*. 27(12):1218-1238. doi:10.1002/gps.3772
70. Bond GE, Burr R, McCurry SM, Graves AB, Larson EB (2001) Alcohol, aging, and cognitive performance in a cohort of Japanese Americans aged 65 and older: the Kame project. *Int Psychogeriatr*. 13(2):207-223. doi:10.1017/s1041610201007591
71. Spencer RL, Hutchison KE (1999) Alcohol, aging, and the stress response. *Alcohol Res Health*. 23(4):272-283.
72. Zhang R, Shen L, Miles T, et al (2020) Association of Low to Moderate Alcohol Drinking with Cognitive Functions from Middle to Older Age Among US Adults. *JAMA Netw Open*. 3(6): e207922. doi:10.1001/jamanetworkopen.2020.7922
73. Ganguli M, Vander Bilt J, Saxton JA, Shen C, Dodge HH (2005) Alcohol consumption and cognitive function in late life A longitudinal community study. *Neurology*. 65 (8) 1210-1217; DOI: 10.1212/01.wnl.0000180520.35181.24
74. Britton A, Singh-Manoux A, Marmot M (2004) Alcohol consumption and cognitive function in the Whitehall II Study. *Am J Epidemiol*. 160(3):240-247. doi:10.1093/aje/kwh206
75. Sun L, Xu H, Zhang J, Li W, Nie J, Qiu Q, Liu Y, Fang Y, Yang Z, Li X and Xiao S (2018) Alcohol Consumption and Subclinical Findings on Cognitive Function, Biochemical Indexes,

- and Cortical Anatomy in Cognitively Normal Aging Han Chinese Population. *Front. Aging Neurosci.* 10:182. doi: 10.3389/fnagi.2018.00182.
76. Topiwala A, Allan CL, Valkanova V, et al (2017) Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. *BMJ.* 357:j2353. Published 2017 Jun 6. doi:10.1136/bmj.j2353
 77. Lobo E, Dufouil C, Marcos G et al (2010) Is there an association between low-to-moderate alcohol consumption and risk of cognitive decline? *Am J Epidemiol.* 172:708–16.
 78. Richard EL, Kritz-Silverstein D, Laughlin GA, Fung TT, Barrett-Connor E, McEvoy LK (2017) Alcohol Intake and Cognitively Healthy Longevity in Community-Dwelling Adults: The Rancho Bernardo Study. *J Alzheimers Dis.* 59(3):803-814. doi:10.3233/JAD-161153
 79. Parker ES, Parker DA, Harford TC (1991). Specifying the relationship between alcohol use and cognitive loss: the effects of frequency of consumption and psychological distress. *Journal of Studies on Alcohol* 52:4, 366-373
 80. Davis BJ, Vidal JS, Garcia M, et al (2014) The alcohol paradox: light-to-moderate alcohol consumption, cognitive function, and brain volume. *J Gerontol A Biol Sci Med Sci.* 69(12):1528-1535. doi:10.1093/gerona/glu092
 81. Vasiliadis HM, Payette MC, Berbiche D, Grenier S, Hudon C (2019) Cognitive decline and alcohol consumption adjusting for functional status over a 3-year period in French speaking community living older adults. *J Public Health (Oxf).* 1;41(2): e177-e184. doi: 10.1093/pubmed/fdy126.
 82. Day AM, Kahler CW, Ahern DC, Clark US (2015) Executive Functioning in Alcohol Use Studies: A Brief Review of Findings and Challenges in Assessment. *Curr Drug Abuse Rev.* 8(1):26-40. doi:10.2174/1874473708666150416110515
 83. Neafsey EJ, Collins MA (2011) Moderate alcohol consumption and cognitive risk. *Neuropsychiatr Dis Treat.* 7: 465–484.
 84. Kim JW, Byun MS, Yi D, et al (2020) Association of moderate alcohol intake with in vivo amyloid-beta deposition in human brain: A cross-sectional study. *PLoS Med.* 17(2): e1003022. Published 2020 Feb 25. doi: 10.1371/journal.pmed.1003022
 85. Wallach JD, Serghiou S, Chu L, et al (2020) Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease. *BMC Med Res Methodol.* 20(1):64. Published 2020 Mar 14. doi:10.1186/s12874-020-0914-6

86. Emberson JR, Bennett DA(2006) Effect of alcohol on risk of coronary heart disease and stroke: causality, bias, or a bit of both? *Vasc Health Risk Manag.* 2(3):239-249. doi:10.2147/vhrm.2006.2.3.239
87. Wootton RE, Greenstone HSR, Abdellaoui A, et al (2020) Bidirectional effects between loneliness, smoking and alcohol use: evidence from a Mendelian randomization study [published online ahead of print, 2020 Jun 15]. *Addiction.* 10.1111/add.15142. doi:10.1111/add.15142
88. Schutte, R, Papageorgiou, M, Najlah, M, et al. Drink types unmask the health risks associated with alcohol intake—prospective evidence from the general population. *Clin Nutr.* Published online February 14, 2020. doi:10.1016/j.clnu.2020.02.009 Google Scholar | Crossref
89. Trevisan M, Schisterman E, Mennotti A, et al (2001) Drinking pattern and mortality: the Italian risk factor and life expectancy pooling project. *Ann Epidemiol.* 11:312–19. [PubMed] [Google Scholar]
90. Hakulinen C, Elovainio M, Batty GD, Virtanen M, Kivimäki M, Jokela M (2015) Personality and alcohol consumption: Pooled analysis of 72,949 adults from eight cohort studies. *Drug Alcohol Depend.* 151:110-114.
91. Stephenson M, Barr P, Ksinan A, et al (2020) Which adolescent factors predict alcohol misuse in young adulthood? A co-twin comparisons study. *Addiction.* 115(5):877-887. doi:10.1111/add.14888
92. Der G, Batty GD, Deary IJ (2009) The association between IQ in adolescence and a range of health outcomes at 40 in the 1979 US National Longitudinal Study of Youth. *Intelligence.* 37(6):573-580. doi:10.1016/j.intell.2008.12.002
93. Cao M, Cui B (2020) Association of Educational Attainment with Adiposity, Type 2 Diabetes, and Coronary Artery Diseases: A Mendelian Randomization Study. *Front Public Health.* 8:112. Published 2020 Apr 22. doi:10.3389/fpubh.2020.00112
94. Zhou T, Sun D, Li X, Ma H et al (2019) Educational attainment and drinking behaviors: Mendelian randomization study in UK Biobank. *Mol Psychiatry.* 25:1-2. <https://doi.org/10.1038/s41380-019-0596-9>
95. Mugavin J, MacLean S, Room R, Callinan S (2020). Adult low-risk drinkers and abstainers are not the same. *BMC public health,* 20(1), 37. <https://doi.org/10.1186/s12889-020-8147-5>
96. Haber JR, Harris-Olenak B, Burroughs T, Jacob T (2016) Residual Effects: Young Adult Diagnostic Drinking Predicts Late-Life Health Outcomes. *J Stud Alcohol Drugs.* 77(6):859-867. doi:10.15288/jsad.2016.77.859

97. Saarni SI, Joutsenniemi K, Koskinen S, et al (2008) Alcohol consumption, abstaining, health utility, and quality of life--a general population survey in Finland. *Alcohol Alcohol*. 43(3):376-386.
98. Fillmore KM, Stockwell T, Chikritzhs T, Bostrom A, Kerr W (2007) Moderate alcohol use and reduced mortality risk: systematic error in prospective studies and new hypotheses. *Ann Epidemiol*. 17(5 Suppl):S16-S23. doi:10.1016/j.annepidem.2007.01.005
99. Gémes K, Janszky I, Strand LB, et al (2018) Light-moderate alcohol consumption and left ventricular function among healthy, middle-aged adults: the HUNT study. *BMJ Open*. 8(5): e020777. Published 2018 May 3. doi:10.1136/bmjopen-2017-020777
100. Kilian C, Manthey J, Probst C, et al (2020) Why Is Per Capita Consumption Underestimated in Alcohol Surveys? Results from 39 Surveys in 23 European Countries [published online ahead of print, 2020 Jun 3]. *Alcohol Alcohol*. agaa048. doi:10.1093/alcalc/agaa048
101. Mukamal KJ, Jensen MK, Gronbaek M, et al (2005) Drinking frequency, mediating biomarkers, and risk of myocardial infarction in women and men. *Circulation*. 112:1406-13. [PubMed] [Google Scholar]
102. Wellmann J, Heidrich J, Berger K, et al (2004) Changes in alcohol intake and risk of coronary heart disease and all-cause mortality in the MONICA/KORA-Augsburg cohort 1987-97. *Eur J Cardiovasc Prev Rehabil*. 11:48-55. [PubMed] [Google Scholar]
103. Wood AM, Kaptoge S, Butterworth AS, et al (2018) Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies [published correction appears in *Lancet*. 2;391(10136):2212]. *Lancet*. 2018;391(10129):1513-1523. doi:10.1016/S0140-6736(18)30134-X
104. Seid AK (2016) Social interactions, trust and risky alcohol consumption. *Health Econ Rev* 6(1):3. <https://doi.org/10.1186/s13561-016-0081-y>
105. Beck AT, Himmelstein R, Bredemeier K, Silverstein SM, Grant P (2018) What accounts for poor functioning in people with schizophrenia: a re-evaluation of the contributions of neurocognitive v. attitudinal and motivational factors. *Psychol Med*. 2018; 48(16): 2776-2785. <https://doi.org/10.1017/S0033291718000442> PMID: 29501072.
106. Moritz S, Irshaid S, Lüdtke T, Schäfer I, Hauschildt M, Lipp M (2018) Neurocognitive Functioning in Alcohol Use Disorder: Cognitive Test Results Do not Tell the Whole Story. *Eur Addict Res*. 24(5):217-225. doi:10.1159/000492160
107. Campellone TR, Sanchez AH, Kring AM (2016) Defeatist Performance Beliefs, Negative Symptoms, and Functional Outcome in Schizophrenia: A Meta-analytic Review. *Schizophr Bull*. 42(6):1343-1352. doi:10.1093/schbul/sbw026

- 108.** Charlton AJ, May C, Luikinga SJ, et al (2019) Chronic voluntary alcohol consumption causes persistent cognitive deficits and cortical cell loss in a rodent model. *Sci Rep.* 9(1):18651. Published 2019 Dec 9. doi:10.1038/s41598-019-55095-w
- 109.** Galaj E, Kipp, BT, Floresco SB, Savage LM (2019). Persistent alterations of accumbal cholinergic interneurons and cognitive dysfunction after adolescent intermittent ethanol exposure. *Neuroscience*, <https://doi.org/10.1016/j.neuroscience.2019.01.062>
- 110.** Cheng Y, Liu X, Ma X, Garcia R, Belfield K, Haorah J (2019) Alcohol promotes waste clearance in the CNS via brain vascular reactivity. *Free Radic Biol Med.* 143:115-126. doi:10.1016/j.freeradbiomed.2019.07.029
- 111.** Ayabe T, Fukuda T, Ano Y (2020) Improving Effects of Hop-Derived Bitter Acids in Beer on Cognitive Functions: A New Strategy for Vagus Nerve Stimulation. *Biomolecules.* 10(1):131. Published 2020 Jan 13. doi:10.3390/biom10010131
- 112.** Ano Y, Takaichi Y, Uchida K, Kondo K, Nakayama H, Takashima A (2018) Iso- α -Acids, the Bitter Components of Beer, Suppress Microglial Inflammation in rTg4510 Tauopathy. *Molecules.* 29;23(12). pii: E3133. doi: 10.3390/molecules23123133. PMID: 30501069 Free PMC Article
- 113.** Lu S, Liao L, Zhang B, et al (2019) Antioxidant cascades confer neuroprotection in ethanol, morphine, and methamphetamine preconditioning. *Neurochem Int.* 131:104540. doi:10.1016/j.neuint.2019.104540
- 114.** Zhou D, Zhao Y, Hook M, et al (2018) Ethanol's Effect on Coq7 Expression in the Hippocampus of Mice. *Front Genet.* 9:602. Published 2018 Dec 4. doi:10.3389/fgene.2018.00602
- 115.** Casañas-Sánchez V, Pérez JA, Quinto-Aleman D, Díaz M (2016) Sub-toxic Ethanol Exposure Modulates Gene Expression and Enzyme Activity of Antioxidant Systems to Provide Neuroprotection in Hippocampal HT22 Cells. *Front Physiol.* 7:312. Published 2016 Jul 27. doi:10.3389/fphys.2016.00312
- 116.** Pignataro L (2019) Alcohol protects the CNS by activating HSF1 and inducing the Heat Shock Proteins. *Neuroscience Letters* 713:134507. DOI: 10.1016/j.neulet.2019.134507
- 117.** Zhou RP, Leng TD, Yang T, Chen FH, Xiong ZG (2019) Acute Ethanol Exposure Promotes Autophagy-Lysosome Pathway-Dependent ASIC1a Protein Degradation and Protects Against Acidosis-Induced Neurotoxicity. *Mol Neurobiol.* 56(5):3326-3340. doi:10.1007/s12035-018-1289-0
- 118.** Su F, Guo AC, Li WW, et al (2017) Low-Dose Ethanol Preconditioning Protects Against Oxygen-Glucose Deprivation/Reoxygenation-Induced Neuronal Injury By Activating Large

- Conductance, Ca²⁺-Activated K⁺ Channels In Vitro. *Neurosci Bull.* 33(1):28-40.
doi:10.1007/s12264-016-0080-3
- 119.**Larsson SC, Burgess S, Mason AM, Michaëlsson K (2020) Alcohol Consumption and Cardiovascular Disease: A Mendelian Randomization Study. *Circ Genom Precis Med.* 13(3):e002814. doi:10.1161/CIRCGEN.119.002814
- 120.**Millwood IY, Walters RG, Mei XW, et al (2019) Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. *Lancet.* 393(10183):1831-1842. doi:10.1016/S0140-6736(18)31772-0
- 121.**Christensen AI, Nordestgaard BG, Tolstrup JS (2018) Alcohol Intake and Risk of Ischemic and Haemorrhagic Stroke: Results from a Mendelian Randomisation Study. *J Stroke.* 20(2):218-227. doi:10.5853/jos.2017.01466
- 122.**Kumari M, Holmes MV, Dale CE et al (2014) Alcohol consumption and cognitive performance: a Mendelian randomization study. *Addiction.* 109(9):1462–71.
- 123.**Clarke TK, Adams MJ, Davies G, et al (2017) Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK Biobank (N=112 117). *Mol Psychiatry.* 22(10):1376-1384. doi:10.1038/mp.2017.153
- 124.**Ho BC, Magnotta V (2010) Hippocampal volume deficits and shape deformities in young biological relatives of schizophrenia probands. *Neuroimage.* 49:3385–3393. [PMC free article] [PubMed] [Google Scholar]
- 125.**Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS (2013) Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. *Schizophr Bull.* 39(5):1129-1138. doi:10.1093/schbul/sbs118
- 126.**Lawrie SM, Abukmeil SS (1998) Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. *Br J Psychiatry.* 172:110-120. doi:10.1192/bjp.172.2.110
- 127.**Lawrie SM (2018) Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective. *Therapeutic Advances in Psychopharmacology,* 319–326. <https://doi.org/10.1177/2045125318782306>